Clinical Trials Logo

Pancreatic Neuroendocrine Tumor clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06167421 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the surgical outcomes of laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique versus the Warshaw technique. The primary focus is on the rates of unplanned splenectomy, occurrence of severe complications, as well as intraoperative and perioperative outcomes of both techniques.

NCT ID: NCT06158516 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.

NCT ID: NCT06024343 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the impact of concomitant main pancreatic duct repair or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.

NCT ID: NCT05847855 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Multi-dimensional Fragmentomic Assay for Early Detection of Pancreatic Neuroendocrine Tumors

Start date: April 27, 2023
Phase:
Study type: Observational

This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors.

NCT ID: NCT03435770 Not yet recruiting - Pancreatic Cancer Clinical Trials

Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

This study aims to evaluate the safety and efficacy of new ablation catheter developed by MEDICAL TAEWOONG for the treatment of pancreatic neoplasm (pancreatic adenocarcinoma or neuroendocrine tumour). The ablation is performed using EUSRA needle and radio frequency waves under ultrasound imaging. The subject who will be recruited into this study are patients who are deemed as non-surgical candidates.

NCT ID: NCT03417843 Not yet recruiting - Pancreatic Cancer Clinical Trials

Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions.

yes
Start date: February 2018
Phase: N/A
Study type: Interventional

This study aims to evaluate the safety and efficacy of new ablation catheter developed by MEDICAL TAEWOONG for the treatment of pancreatic premalignant and early malignant cystic lesion. The ablation is performed using EUSRA needle and radiofrequncy waves under ultrasound imaging. The method will be exaimened on patients who are candidates for surgical intervention and to examine the ability of the method to serve as an alternative to surgical intervention.

NCT ID: NCT02624154 Not yet recruiting - Clinical trials for Pancreatic Neuroendocrine Tumor

Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival

Start date: December 2015
Phase: N/A
Study type: Observational

Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.